Treatment with rTS‐SUCLA‐β, similar to other helminth infections, induces an elevation in IL‐10 levels, indicating that the immunomodulatory effects of rTS‐SUCLA‐β are mediated through activation of the regulatory pathway within the immune system. Here, IL10 is linked to helminthiasis.